Form 4: Crinetics Pharmaceuticals CFO Marc Wilson Executes Option and Sells Shares
SEC Form 4 Filing
CFO Marc Wilson exercised stock options and sold shares of Crinetics Pharmaceuticals on July 25, 2024, according to a Form 4 filing with the SEC.
Summary
- On July 25, 2024, Marc Wilson, CFO of Crinetics Pharmaceuticals, exercised options to purchase 19,056 shares of common stock at a price of $9.28 per share.
- Simultaneously, Wilson sold 19,056 shares of common stock in the open market at a weighted average price of $53.88 per share.
- Following these transactions, Wilson directly owns 111,092 shares of Crinetics Pharmaceuticals common stock.
- The sale was executed automatically pursuant to a pre-arranged Rule 10b5-1 trading plan.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports transactions. The use of a 10b5-1 plan suggests pre-planned and potentially unemotional trading.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.
Key Dates
| Date | Description |
|---|---|
| 06/25/2018 | 1/48th of the shares subject to the option vested. |
| 05/24/2028 | Expiration date of the stock option. |
| 07/25/2024 | Date of the stock option exercise and share sale. |
| 07/26/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.